China Biotech Services Holdings Limited

Informe Stock SEHK:8037

Capitalización de mercado: HK$269.7m

China Biotech Services Holdings Resultados de beneficios anteriores

Pasado controles de criterios 0/6

China Biotech Services Holdings ha aumentado sus ingresos a un ritmo medio anual de 47.7%, mientras que la industria Healthcare ha visto aumentar sus ingresos growing a 6.6% anualmente. Los ingresos han crecido growing a un ritmo medio anual de 40.2%.

Información clave

47.7%

Tasa de crecimiento de los beneficios

48.1%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare 11.3%
Tasa de crecimiento de los ingresos40.2%
Rentabilidad financiera-28.7%
Margen neto-45.0%
Última actualización de beneficios31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

China Biotech Services Holdings Limited's (HKG:8037) Popularity With Investors Under Threat As Stock Sinks 31%

Mar 07
China Biotech Services Holdings Limited's (HKG:8037) Popularity With Investors Under Threat As Stock Sinks 31%

Earnings Not Telling The Story For China Biotech Services Holdings Limited (HKG:8037) After Shares Rise 46%

Jan 18
Earnings Not Telling The Story For China Biotech Services Holdings Limited (HKG:8037) After Shares Rise 46%

We Think China Biotech Services Holdings (HKG:8037) Might Have The DNA Of A Multi-Bagger

Jan 06
We Think China Biotech Services Holdings (HKG:8037) Might Have The DNA Of A Multi-Bagger

Does China Biotech Services Holdings (HKG:8037) Have A Healthy Balance Sheet?

Dec 09
Does China Biotech Services Holdings (HKG:8037) Have A Healthy Balance Sheet?

These 4 Measures Indicate That China Biotech Services Holdings (HKG:8037) Is Using Debt Safely

Aug 24
These 4 Measures Indicate That China Biotech Services Holdings (HKG:8037) Is Using Debt Safely

A Look At The Fair Value Of China Biotech Services Holdings Limited (HKG:8037)

Nov 05
A Look At The Fair Value Of China Biotech Services Holdings Limited (HKG:8037)

Is China Biotech Services Holdings (HKG:8037) A Risky Investment?

Oct 13
Is China Biotech Services Holdings (HKG:8037) A Risky Investment?

What China Biotech Services Holdings Limited's (HKG:8037) 35% Share Price Gain Is Not Telling You

Jun 28
What China Biotech Services Holdings Limited's (HKG:8037) 35% Share Price Gain Is Not Telling You

China Biotech Services Holdings (HKG:8037) Could Become A Multi-Bagger

Mar 16
China Biotech Services Holdings (HKG:8037) Could Become A Multi-Bagger

China Biotech Services Holdings (HKG:8037) Knows How To Allocate Capital Effectively

Dec 01
China Biotech Services Holdings (HKG:8037) Knows How To Allocate Capital Effectively

Under The Bonnet, China Biotech Services Holdings' (HKG:8037) Returns Look Impressive

Jul 26
Under The Bonnet, China Biotech Services Holdings' (HKG:8037) Returns Look Impressive

China Biotech Services Holdings' (HKG:8037) Robust Earnings Are Supported By Other Strong Factors

Apr 05
China Biotech Services Holdings' (HKG:8037) Robust Earnings Are Supported By Other Strong Factors

Investors Shouldn't Overlook China Biotech Services Holdings' (HKG:8037) Impressive Returns On Capital

Mar 23
Investors Shouldn't Overlook China Biotech Services Holdings' (HKG:8037) Impressive Returns On Capital

Did You Miss China Biotech Services Holdings' (HKG:8037) Whopping 825% Share Price Gain?

Feb 23
Did You Miss China Biotech Services Holdings' (HKG:8037) Whopping 825% Share Price Gain?

Chun-Shun Ko Just Bought 27% More Shares In China Biotech Services Holdings Limited (HKG:8037)

Jan 28
Chun-Shun Ko Just Bought 27% More Shares In China Biotech Services Holdings Limited (HKG:8037)

What Is The Ownership Structure Like For China Biotech Services Holdings Limited (HKG:8037)?

Jan 11
What Is The Ownership Structure Like For China Biotech Services Holdings Limited (HKG:8037)?

The Trend Of High Returns At China Biotech Services Holdings (HKG:8037) Has Us Very Interested

Dec 08
The Trend Of High Returns At China Biotech Services Holdings (HKG:8037) Has Us Very Interested

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero China Biotech Services Holdings. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

SEHK:8037 Ingresos, gastos y beneficios (HKD Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
31 Dec 23212-951520
30 Sep 23776332060
30 Jun 231,3471592350
31 Mar 231,5982082450
31 Dec 221,8522582590
30 Sep 221,394742220
30 Jun 2293732040
31 Mar 22854531900
31 Dec 21624191690
30 Sep 216141131590
30 Jun 219991551570
31 Mar 21797541530
31 Dec 20656301440
30 Sep 20564-211300
30 Jun 2062-1051150
31 Mar 2058-1061130
31 Dec 1959-991040
30 Sep 1962-761030
30 Jun 1965-721010
31 Mar 1967-66950
31 Dec 1870-64960
30 Sep 1875-95910
30 Jun 1879-83800
31 Mar 1888-48730
31 Dec 17105-63690
30 Sep 17111-48610
30 Jun 17113-64640
31 Mar 17104-103710
31 Dec 1687-86730
30 Sep 1669-81720
30 Jun 1652-84620
31 Mar 1639-72500
31 Dec 1534-54440
30 Sep 153-36190
30 Jun 1538-21270
31 Mar 1556-43350
31 Dec 1470-75470
30 Sep 14111-85750
30 Jun 1492-84730
31 Mar 1489-79690
31 Dec 1385-60590
30 Sep 1381-44520
30 Jun 1311315520

Ingresos de calidad: 8037 actualmente no es rentable.

Margen de beneficios creciente: 8037 actualmente no es rentable.


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: 8037 no es rentable, pero ha reducido pérdidas en los últimos 5 años a un ritmo de 47.7% por año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de 8037 en el último año con su media de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: 8037 no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el del sector Healthcare (9.8%).


Rentabilidad financiera

Alta ROE: 8037 tiene un Rendimiento de los fondos propios negativo (-28.67%), ya que actualmente no es rentable.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target